HRP20120350T1 - Novi oblici cddo metilnog estera - Google Patents
Novi oblici cddo metilnog estera Download PDFInfo
- Publication number
- HRP20120350T1 HRP20120350T1 HRP20120350AT HRP20120350T HRP20120350T1 HR P20120350 T1 HRP20120350 T1 HR P20120350T1 HR P20120350A T HRP20120350A T HR P20120350AT HR P20120350 T HRP20120350 T HR P20120350T HR P20120350 T1 HRP20120350 T1 HR P20120350T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- methyl ester
- cddo
- excipient
- glassy
- Prior art date
Links
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 title claims abstract 11
- 239000007787 solid Substances 0.000 claims abstract 8
- 239000000843 powder Substances 0.000 claims abstract 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 230000009477 glass transition Effects 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- -1 organic acid salt Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229920005613 synthetic organic polymer Polymers 0.000 claims 2
- BXGYYDRIMBPOMN-UHFFFAOYSA-N 2-(hydroxymethoxy)ethoxymethanol Chemical compound OCOCCOCO BXGYYDRIMBPOMN-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical group O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Glass Compositions (AREA)
Abstract
Staklasto-kruti oblik CDDO metilnog estera, naznačen time da čiji rendgenski difraktogram praha ima amorfni halo na približno 13,5 °2θ, kao što je prikazano na Slici 2C, i koji ima Tg.Patent sadrži još 17 patentnih zahtjeva.
Claims (18)
1. Staklasto-kruti oblik CDDO metilnog estera, naznačen time da čiji rendgenski difraktogram praha ima amorfni halo na približno 13,5 °2θ, kao što je prikazano na Slici 2C, i koji ima Tg.
2. Dimetanolni solvat CDDO-metilnog estera, naznačen time da čiji rendgenski difraktogram praha ima karakteristične maksimume kako je prikazano u Tablici 18 i DSC signal kako je prikazano u Slici 24.
3. Farmaceutski pripravak u krutom doznom obliku, naznačen time da sadrži (i) terapijski učinkovitu količinu staklasto-krutog CDDO metil-estera iz Zahtjeva 1 i (ii) jestivi nosač.
4. Metoda za proizvodnju staklasto-krutog oblika CDDO-metilnog estera iz zahtjeva 1, naznačena time da obuhvaća (a) pripremu dimetanolnog solvata CDDO- metilnog estera, čiji rendgenski difraktogram praha ima maksimume kako je prikazano u Tablici 18 i DSC signal kako je prikazano na Slici 24, te (b) sušenje dimetanolnog solvata radi dobivanja navedenog staklasto-krutog oblika.
5. Staklasto-kruti oblik CDDO-metilnog estera iz Zahtjeva 1, naznačen time da ima PDF spektar s karakterističnim maksimumima iz Slike 28 od približno 5 Å do približno 20 Å.
6. Farmaceutski pripravak sukladno Zahtjevu 3 naznačen time da je za primjenu u liječenju kanceroznih stanja.
7. Farmaceutski pripravak sukladno Zahtjevu 6, naznačen time da dodatno sadrži drugi lijek protiv raka.
8. Farmaceutski pripravak sukladno Zahtjevu 7, naznačen time da drugi lijek protiv raka pripada skupini gemcitabina, a kancerozno stanje je rak gušterače.
9. Staklasto-kruti oblik CDDO-metilnog estera iz zahtjeva 1, naznačen time da ima staklište (Tg) između 120°C i 135°C.
10. Staklasto-kruti oblik CDDO-metilnog estera iz zahtjeva 1, naznačen time da ima staklište (Tg) između 125°C i 135°C.
11. Farmaceutski pripravak naznačen time da sadrži (i) terapijski učinkovitu količinu CDDO-metilnog estera i (ii) ekscipijent koji pomaže stvoriti staklastu fazu, tako da navedeni pripravak ima Tg.
12. Farmaceutski pripravak iz zahtjeva 11, naznačen time da je ekscipijent odabran iz skupine koja se sastoji od (A) ugljikohidrata, derivata ugljikohidrata ili polimera ugljikohidrata, (B) sintetskog organskog polimera, (C) soli organske kiseline, (D) proteina, polipeptida ili peptida i (E) polisaharida visoke molekularne težine.
13. Farmaceutski pripravak iz zahtjeva 12, naznačen time da je ekscipijent sintetski organski polimer.
14. Farmaceutski pripravak iz zahtjeva 13, naznačen time da je ekscipijent odabran iz skupine koja se sastoji od hidroksipropil metil celuloze, poli[1-(2-okso-1-pirolidinil)etilena ili njegovog kopolimera, te kopolimera metakrilne kiseline.
15. Farmaceutski pripravak iz Zahtjeva 14, naznačen time da je ekscipijent ftalatni ester hidroksipropil metil celuloze.
16. Farmaceutski pripravak iz Zahtjeva 14, naznačen time da je ekscipijent PVP/VA.
17. Farmaceutski pripravak iz Zahtjeva 14, naznačen time da je ekscipijent metakrilna kiselina–etil akrilatni kopolimer (1:1).
18. Farmaceutski pripravak iz Zahtjeva 13, naznačen time da je ekscipijent kopovidon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95593907P | 2007-08-15 | 2007-08-15 | |
| PCT/US2008/009703 WO2009023232A1 (en) | 2007-08-15 | 2008-08-14 | Novel forms of cddo methyl ester |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120350T1 true HRP20120350T1 (hr) | 2012-05-31 |
Family
ID=40351005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120350AT HRP20120350T1 (hr) | 2007-08-15 | 2012-04-18 | Novi oblici cddo metilnog estera |
| HRP20161503TT HRP20161503T1 (hr) | 2007-08-15 | 2016-11-15 | Novi oblici cddo metilnog estera |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161503TT HRP20161503T1 (hr) | 2007-08-15 | 2016-11-15 | Novi oblici cddo metilnog estera |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8088824B2 (hr) |
| EP (2) | EP2187741B1 (hr) |
| JP (4) | JP5005812B2 (hr) |
| KR (2) | KR101544766B1 (hr) |
| CN (2) | CN103254267B (hr) |
| AR (2) | AR073155A1 (hr) |
| AT (1) | ATE549035T1 (hr) |
| AU (1) | AU2008287388B2 (hr) |
| BR (1) | BRPI0815540A8 (hr) |
| CA (2) | CA2696330C (hr) |
| CL (1) | CL2008002417A1 (hr) |
| CY (2) | CY1112864T1 (hr) |
| DK (2) | DK2450057T3 (hr) |
| EA (2) | EA023550B1 (hr) |
| ES (2) | ES2382571T3 (hr) |
| HK (1) | HK1143537A1 (hr) |
| HR (2) | HRP20120350T1 (hr) |
| HU (1) | HUE031866T2 (hr) |
| IL (2) | IL203824A (hr) |
| LT (1) | LT2450057T (hr) |
| MX (1) | MX2010001628A (hr) |
| NZ (1) | NZ583269A (hr) |
| PL (2) | PL2187741T3 (hr) |
| PT (2) | PT2450057T (hr) |
| SG (2) | SG10201504650VA (hr) |
| SI (2) | SI2187741T1 (hr) |
| TW (2) | TWI419899B (hr) |
| WO (1) | WO2009023232A1 (hr) |
| ZA (1) | ZA201001066B (hr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) * | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| EP1465615B1 (en) | 2002-01-15 | 2012-08-01 | Trustees of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
| JP2010510243A (ja) | 2006-11-17 | 2010-04-02 | トラスティーズ オブ ダートマス カレッジ | 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性 |
| WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| RS58486B1 (sr) * | 2008-01-11 | 2019-04-30 | Reata Pharmaceuticals Inc | Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti |
| BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
| PL2276493T3 (pl) * | 2008-04-18 | 2019-05-31 | Reata Pharmaceuticals Inc | Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17 |
| CN102066397B (zh) | 2008-04-18 | 2013-09-11 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
| CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
| TW201004627A (en) | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| KR101483203B1 (ko) * | 2009-02-13 | 2015-01-15 | 리아타 파마슈티컬즈, 아이엔씨. | 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물 |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| ME03713B (me) | 2010-04-12 | 2021-01-20 | Reata Pharmaceuticals Inc | Bardoksolon meтil za lečenje gojaznosтi |
| PL2651902T3 (pl) | 2010-12-17 | 2018-04-30 | Reata Pharmaceuticals, Inc. | Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym |
| UY33946A (es) | 2011-03-11 | 2012-08-31 | Reata Pharmaceuticals Inc | Derivados de c4-monometil triterpenoides y sus métodos de uso |
| CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
| PT2841445T (pt) | 2012-04-27 | 2017-09-01 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| CA2884400A1 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| PE20150627A1 (es) | 2012-09-10 | 2015-06-04 | Reata Pharmaceuticals Inc | Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso |
| JP5972986B2 (ja) | 2012-09-28 | 2016-08-17 | アプライド ファーマシューティカル サイエンス インコーポレイテッド | Ｃｄｄｏエチルエステルの多形体及びその用途 |
| CN102887936A (zh) * | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
| CN102875634B (zh) * | 2012-10-24 | 2014-08-20 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 |
| EP2977381B1 (en) | 2013-03-19 | 2018-09-26 | Daiichi Sankyo Company, Limited | Terpenoid derivative |
| TW201936625A (zh) | 2013-04-24 | 2019-09-16 | 美商艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| SG10201906113RA (en) * | 2013-08-23 | 2019-08-27 | Reata Pharmaceuticals Inc | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| WO2016033132A1 (en) | 2014-08-26 | 2016-03-03 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
| US10189791B2 (en) | 2014-08-26 | 2019-01-29 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
| CN106661080A (zh) | 2014-09-10 | 2017-05-10 | 第三共株式会社 | 用于治疗和预防眼科疾病的缓释药物组合物 |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| US11591302B2 (en) | 2014-12-19 | 2023-02-28 | Geistlich Pharm A Ag | Processes for preparing oxathiazin-like compounds |
| HRP20220313T1 (hr) | 2014-12-19 | 2022-05-13 | Geistlich Pharma Ag | Procesi za pripremu spojeva sličnih oksatiazinu |
| JP6748652B2 (ja) | 2015-02-12 | 2020-09-02 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン |
| PL3317281T3 (pl) * | 2015-07-02 | 2020-11-02 | Acerta Pharma B.V. | Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu |
| EA201890767A1 (ru) | 2015-09-23 | 2019-09-30 | Рита Фармасьютикалз, Инк. | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений |
| US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| WO2019014412A1 (en) | 2017-07-13 | 2019-01-17 | Pliva Hrvatska D.O.O. | NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE |
| CN112654610A (zh) | 2018-06-15 | 2021-04-13 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| TW202038918A (zh) | 2018-11-27 | 2020-11-01 | 日商協和麒麟股份有限公司 | 醫藥組合物 |
| US20230255982A1 (en) | 2020-05-09 | 2023-08-17 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
| EP4259155A1 (en) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07121911B2 (ja) * | 1986-03-26 | 1995-12-25 | クミアイ化学工業株式会社 | ４（１ｈ）−ピリジノン誘導体および農園芸用殺菌剤 |
| JPH01273020A (ja) * | 1988-04-26 | 1989-10-31 | Toray Ind Inc | 有機非線形光学材料 |
| US5064823A (en) * | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| JP2876144B2 (ja) * | 1990-03-23 | 1999-03-31 | 東洋フアルマー株式会社 | ３―フェニルクマリン―７―イルオキシ酢酸誘導体とその製法及び用途 |
| GB9622173D0 (en) * | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| US20050276836A1 (en) * | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6890946B2 (en) * | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
| US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| AU2002243246A1 (en) * | 2000-11-28 | 2002-06-24 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| CA2485565A1 (en) * | 2002-05-13 | 2004-08-05 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
| JP3618341B2 (ja) * | 2003-04-15 | 2005-02-09 | 山之内製薬株式会社 | 臭化物及びその結晶 |
| FR2861299B1 (fr) * | 2003-10-28 | 2006-01-27 | Pf Medicament | Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes |
| WO2005057275A1 (ja) | 2003-12-08 | 2005-06-23 | Sony Corporation | 液晶表示装置およびバックライト調整方法 |
| US20060167097A1 (en) * | 2004-04-16 | 2006-07-27 | Cheppail Ramachandran | Compositions and uses of Amooranin compounds |
| WO2006127926A2 (en) * | 2005-05-23 | 2006-11-30 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
| NZ569078A (en) | 2005-12-12 | 2012-01-12 | Mosamedix Bv | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
| US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
-
2008
- 2008-08-13 US US12/191,176 patent/US8088824B2/en active Active
- 2008-08-14 AU AU2008287388A patent/AU2008287388B2/en active Active
- 2008-08-14 BR BRPI0815540A patent/BRPI0815540A8/pt not_active Application Discontinuation
- 2008-08-14 HU HUE12153605A patent/HUE031866T2/en unknown
- 2008-08-14 AR ARP080103557A patent/AR073155A1/es unknown
- 2008-08-14 PL PL08795303T patent/PL2187741T3/pl unknown
- 2008-08-14 CA CA2696330A patent/CA2696330C/en active Active
- 2008-08-14 SI SI200830650T patent/SI2187741T1/sl unknown
- 2008-08-14 PT PT121536056T patent/PT2450057T/pt unknown
- 2008-08-14 CL CL2008002417A patent/CL2008002417A1/es unknown
- 2008-08-14 MX MX2010001628A patent/MX2010001628A/es active IP Right Grant
- 2008-08-14 SI SI200831728A patent/SI2450057T1/sl unknown
- 2008-08-14 DK DK12153605.6T patent/DK2450057T3/en active
- 2008-08-14 SG SG10201504650VA patent/SG10201504650VA/en unknown
- 2008-08-14 TW TW097130947A patent/TWI419899B/zh active
- 2008-08-14 AT AT08795303T patent/ATE549035T1/de active
- 2008-08-14 TW TW102134576A patent/TWI486357B/zh active
- 2008-08-14 CN CN201310016448.8A patent/CN103254267B/zh active Active
- 2008-08-14 PT PT08795303T patent/PT2187741E/pt unknown
- 2008-08-14 KR KR1020147002848A patent/KR101544766B1/ko active IP Right Grant
- 2008-08-14 SG SG2011094158A patent/SG177905A1/en unknown
- 2008-08-14 EP EP08795303A patent/EP2187741B1/en active Active
- 2008-08-14 KR KR1020107005094A patent/KR101481764B1/ko active IP Right Grant
- 2008-08-14 LT LTEP12153605.6T patent/LT2450057T/lt unknown
- 2008-08-14 ES ES08795303T patent/ES2382571T3/es active Active
- 2008-08-14 DK DK08795303.0T patent/DK2187741T3/da active
- 2008-08-14 EA EA201370109A patent/EA023550B1/ru unknown
- 2008-08-14 CA CA2871864A patent/CA2871864C/en active Active
- 2008-08-14 EA EA201070149A patent/EA018704B1/ru unknown
- 2008-08-14 EP EP12153605.6A patent/EP2450057B1/en active Active
- 2008-08-14 WO PCT/US2008/009703 patent/WO2009023232A1/en active Application Filing
- 2008-08-14 NZ NZ583269A patent/NZ583269A/en unknown
- 2008-08-14 CN CN2008801112346A patent/CN101820758B/zh active Active
- 2008-08-14 PL PL12153605T patent/PL2450057T3/pl unknown
- 2008-08-14 ES ES12153605.6T patent/ES2602978T3/es active Active
- 2008-08-14 JP JP2010521031A patent/JP5005812B2/ja active Active
-
2010
- 2010-02-09 IL IL203824A patent/IL203824A/en active IP Right Grant
- 2010-02-12 ZA ZA201001066A patent/ZA201001066B/xx unknown
- 2010-10-25 HK HK10110040.7A patent/HK1143537A1/xx unknown
-
2011
- 2011-11-29 US US13/306,043 patent/US8309601B2/en active Active
-
2012
- 2012-04-18 HR HRP20120350AT patent/HRP20120350T1/hr unknown
- 2012-05-23 JP JP2012117773A patent/JP2012188438A/ja active Pending
- 2012-06-13 CY CY20121100542T patent/CY1112864T1/el unknown
- 2012-06-29 US US13/537,583 patent/US8633243B2/en active Active
-
2015
- 2015-05-07 JP JP2015094538A patent/JP2015164939A/ja active Pending
-
2016
- 2016-11-15 HR HRP20161503TT patent/HRP20161503T1/hr unknown
- 2016-11-23 CY CY20161101205T patent/CY1118329T1/el unknown
-
2017
- 2017-03-27 IL IL251419A patent/IL251419A0/en unknown
- 2017-08-10 JP JP2017154939A patent/JP2018009001A/ja active Pending
-
2020
- 2020-03-25 AR ARP200100825A patent/AR119704A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120350T1 (hr) | Novi oblici cddo metilnog estera | |
| CN104968646B (zh) | Zeste同源物增强子2的抑制剂 | |
| CN105143187A (zh) | 制备磺酰氯化合物的方法 | |
| HRP20120007T1 (hr) | Polimorfni oblik 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona | |
| CN112823151A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
| RU2016149485A (ru) | Твердые формы ромидепсина и их применение | |
| JP2015078220A5 (hr) | ||
| MA31571B1 (fr) | Composes organiques | |
| CZ2012537A3 (cs) | Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití | |
| TW201431552A (zh) | 醫藥組成物 | |
| IL202600A0 (en) | Azaindole-indole coupled derivatives, preparation methods and uses thereof | |
| WO2008024980A3 (en) | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives | |
| CN107148419A (zh) | Zeste增强子同源物2抑制剂 | |
| TW202126622A (zh) | 用於治療與ｓｔｉｎｇ活性相關之病狀的化合物及組合物 | |
| Lu et al. | Synthesis and synergetic anti-tumor activity evaluation of dihydroartemisinin-organogermanium (IV) compound | |
| HRP20141172T1 (hr) | Disupstituirani spojevi tetrahidrofuranila kao antagonisti receptora bradikinina b1 | |
| CN116261452A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN102448953B (zh) | 吡唑化合物 | |
| EA200700818A1 (ru) | Производные 1,2,4-триазолиламиноарил(гетероарил)сульфонамидов | |
| CN103393604B (zh) | 枸橼酸他莫昔芬肠溶颗粒 | |
| SI2601214T1 (en) | VEGF antagonist compositions and their use | |
| CN103142533B (zh) | 一种依托泊苷肠溶片 | |
| CN103349648B (zh) | 枸橼酸他莫昔芬肠溶片 | |
| CN109336891B (zh) | 5-（呋喃-2’-羰基）-2,3-二氢-1h-吡咯嗪-7-羧酸及其衍生物 |